Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Americas
Canada-based Bausch Health has agreed to settle its dispute with generic maker Sandoz over the latter’s attempt to release a generic version of antibiotic Xifaxan.   7 May 2020
Big Pharma
The exciting field of microbiome therapeutics offers many opportunities for ‘Big Pharma’ players that are staring over the exclusivity cliff, say Craig Thomson, Leena Contarino and Andrew Wells of HGF.   6 May 2020
Americas
Criminal investigators in the US Homeland Security Investigations’ National Intellectual Property Rights Coordination Center have partnered with Pfizer, 3M, Citi, Alibaba, Amazon and Merck & Co to combat fraud and other illegal activity related to COVID-19.   6 May 2020
Americas
US customs authorities have seized tens of thousands of counterfeit and unapproved COVID-19 test kits, largely sent through the postal system, since the beginning of the pandemic.   5 May 2020
Asia-Pacific
An Australian federal judge has thrown out a challenge by Gilead Sciences to the wording of infringement claims made by a GlaxoSmithKline subsidiary.   5 May 2020
Americas
3M has filed four more trademark lawsuits against companies accused of reselling N95 masks at inflated prices amid the COVID-19 pandemic, while also securing a preliminary injunction in another suit.   5 May 2020
Big Pharma
Once a genuine vaccine against COVID-19 has been announced, counterfeiters and fraudsters are likely to invest heavily in offering ineffective counterfeit versions of the vaccine online, according to Europol.   1 May 2020
Biotechnology
The University of Oxford has partnered with UK pharmaceutical company AstraZeneca to develop and manufacture the university’s trial COVID-19 vaccine.   30 April 2020
Big Pharma
The Court of Justice of the European Union has handed down its decision in Royalty Pharma, providing highly-anticipated guidance on supplementary protection certificates.   30 April 2020
Americas
Foreign patents protecting COVID-19 treatments may stall efforts to protect citizens, says Mark Engelman of Hardwicke chambers.   30 April 2020